Allschwil, Switzerland
Engimmune Therapeutics, founded in 2021, is an innovative company based in a new science park in Allschwill, Basel, Switzerland, targeting the biotechnology, health and wellness, and pharmaceutical industries. The company is dedicated to the development of next-generation T cell receptor (TCR) therapies against cancer and other serious human diseases with high unmet medical need, focusing its efforts primarily on oncology.
Engimmune leverages a proprietary high-throughput technology platform created through its unique protein engineering toolbox. This platform supports the discovery of potent and safe TCR-based cell therapies and biotherapeutics, covering the entire TCR discovery value chain. The company positions itself as a platform technology and product development enterprise with global ambitions.
In a key financing round, Engimmune secured a Fr.15.50M spinout investment in May 2022 from prominent investors such as Novo Holdings, BB Pureos Bioventures, and Novo Seeds. This investment underscores the confidence these investors have in Engimmune's potential to disrupt the field of immunotherapy.
